<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954171</url>
  </required_header>
  <id_info>
    <org_study_id>19 GENF 01</org_study_id>
    <nct_id>NCT03954171</nct_id>
  </id_info>
  <brief_title>Platino-resistance in Ovarian Cancer</brief_title>
  <acronym>PlatinOv</acronym>
  <official_title>Platino-resistance in Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric study aiming to identify factors involved in platinum&#xD;
      based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).&#xD;
&#xD;
      Patients will receive treatment (platinum based-chemotherapy) according to the standard&#xD;
      practices.&#xD;
&#xD;
      A prospective database and an associated biological collection will be performed during 5&#xD;
      years:&#xD;
&#xD;
        -  For each patient: clinical, biological, epidemiological and therapeutic treatment data&#xD;
           will be collected during the standard therapeutic care.&#xD;
&#xD;
        -  Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be&#xD;
           collected for all patients. These samples will be collected at the same time as those&#xD;
           taken in standard practice (no additional biopsy will be performed for the study).&#xD;
&#xD;
      Study participation of each patient will be 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">May 2029</completion_date>
  <primary_completion_date type="Anticipated">May 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients alive without progression</measure>
    <time_frame>5 years for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to onset of platinum based-chemotherapy resistance</measure>
    <time_frame>5 years for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Patients treated with platinum based-chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients treated with platinum based-chemotherapy</intervention_name>
    <description>Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):&#xD;
before treatment initiation (blood sample),&#xD;
during hospitalisation for surgery (blood sample),&#xD;
during follow-up consultations (blood sample).&#xD;
If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.</description>
    <arm_group_label>Patients treated with platinum based-chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old&#xD;
&#xD;
          2. Epithelial ovarian cancer at initial diagnosis (all stages)&#xD;
&#xD;
          3. Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant&#xD;
             treatment&#xD;
&#xD;
          4. Indication of platinum based-chemotherapy&#xD;
&#xD;
          5. Patient affiliated to the french social security system&#xD;
&#xD;
          6. Patient must provide written informed consent prior to inclusion in the study and any&#xD;
             study-specific procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-epithelial ovarian tumor, borderline ovarian tumor&#xD;
&#xD;
          2. Patient with recurrent disease&#xD;
&#xD;
          3. Exploratory surgery not performed at the &quot;Institut Universitaire du Cancer de Toulouse&#xD;
             - Oncopole (IUCT-O)&quot;&#xD;
&#xD;
          4. Pregnant or breastfeeding women&#xD;
&#xD;
          5. Any psychological, familial, geographical or sociological condition potentially&#xD;
             preventing the medical follow-up and/or study procedures&#xD;
&#xD;
          6. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under legal protection (curatorship and guardianship, protection of justice)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gwenaël FERRON</last_name>
    <phone>05 31 15 53 55</phone>
    <email>Ferron.Gwenael@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaël FERRON</last_name>
      <phone>05 31 15 53 55</phone>
      <email>Ferron.Gwenael@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <keyword>Platinum based-chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

